For as long as I’ve been a healthcare reporter, the JP Morgan Healthcare Conference has served as a newsy way … Get ...
Daiichi Sankyo is spending $132.5 million to buy an antibody outright that it had already licensed from Glycotope.
IgA1 reduction in 4 hours, outperforming Vertex's povetacicept and Otsuka's sibeprenlimab. Plans for Phase 3 in IgAN.
IgA1 reduction in 4 hours, outperforming Vertex's povetacicept and Otsuka's sibeprenlimab. Plans for Phase 3 in IgAN.
XO Health launches health plan in 4 cities, offering employers alternative coverage with fixed-price care packages and ...
Former FDA Commissioner Scott Gottlieb said Robert F. Kennedy Jr. should not lead the US health agencies, underscoring the risk of further eroding faith in vaccines.
Moderna is slashing its 2025 revenue estimate by $1 billion and expanding cost-cutting measures as it continues to struggle ...
The US Court of Appeals for the Federal Circuit on Friday found a key patent of Novartis' Entresto valid, reversing a lower ...
Is the frenzy of JPM dealmaking finally underway? GSK announced Monday morning that it will acquire the privately-held ...
Immunovant secures $450M private placement for IMVT-1402 development, while Biomea shifts focus to diabetes, and multiple companies announce deals and organizational changes.
L1 pioneer Lieping Chen has closed a new financing round. Normunity raised $75 million in a Series B, the company announced Monday, which it hopes to use to advance its lead program NRM-823 into the ...
Indian CDMO Aragen has secured a $100 million investment from Singapore-headquartered private equity firm Quadria Capital.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback